2022 Hepatitis D Drugs in Development Report – Featuring Antios Therapeutics, CN Bio Innovations, Eiger BioPharmaceuticals and Gilead Sciences Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hepatitis D Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Companies Mentioned

• Albireo Pharma Inc
• Antios Therapeutics Inc
• CN Bio Innovations Ltd
• Eiger BioPharmaceuticals Inc
• F. Hoffmann-La Roche Ltd
• Gilead Sciences Inc
• Globeimmune Inc
• Huahui Anjian (Beijing) Biotechnology Co Ltd
• Johnson & Johnson
• Merck & Co Inc
• PharmaEssentia Corp
• Replicor Inc
• Rodos BioTarget GmbH
• SomaGenics Inc
• Svenska Vaccinfabriken Produktion AB
• Vir Biotechnology Inc

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

Report Highlights

The report provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4, 1, 8 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 3 molecules, respectively.

Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

For more information about this report visit https://www.researchandmarkets.com/r/v4kpdo

Source: Global Markets Direct

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900